Literature DB >> 32878846

Systemic lupus erythematosus presenting as thrombotic thrombocytopaenic purpura in a child: a diagnostic challenge.

Irene Alejandra Orbe Jaramillo1, Carmen De Lucas Collantes2, Amelia Martínez de Azagra3, Elena Sebastián4.   

Abstract

Thrombotic thrombocytopaenic purpura (TTP) is a life-threatening thrombotic microangiopathy characterised by microangiopathic haemolytic anaemia, thrombocytopaenia and organ ischaemia. TTP is caused by a severe functional deficiency of ADAMTS13 activity. We describe a 10-year-old girl presenting anaemia and thrombocytopaenia with schistocytes. Urine protein to creatinine ratio was within nephrotic range. ADAMTS13 activity was 0%, and no anti-ADAMTS13 antibodies were found. A renal biopsy showed deposits of IgG, C3 and C1q in the capillary membrane, compatible with class V lupus nephritis. Therapeutic plasma exchange (TPE) was performed in conjunction with therapy consisting of steroids and mycophenolate mofetil. After 11 months of follow-up, the patient remains in remission with normal ADAMTS13 activity. Although acquired TTP is a rare finding in children, differential diagnosis of thrombotic microangiopathy should include ADAMTS13 and the assay should be performed early. TTP treatment is based on TPE, although the underlying disease must be ruled out to optimise treatment and prevent relapse. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  haematology (drugs and medicines); paediatric prescribing

Mesh:

Substances:

Year:  2020        PMID: 32878846      PMCID: PMC7470485          DOI: 10.1136/bcr-2019-232002

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Pediatric thrombotic thrombocytopenic purpura.

Authors:  Bérangère S Joly; Paul Coppo; Agnès Veyradier
Journal:  Eur J Haematol       Date:  2018-08-22       Impact factor: 2.997

2.  Complement activation in thrombotic thrombocytopenic purpura.

Authors:  M Réti; P Farkas; D Csuka; K Rázsó; Á Schlammadinger; M L Udvardy; K Madách; G Domján; C Bereczki; G S Reusz; A J Szabó; Z Prohászka
Journal:  J Thromb Haemost       Date:  2012-05       Impact factor: 5.824

3.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.

Authors:  Michelle Petri; Ana-Maria Orbai; Graciela S Alarcón; Caroline Gordon; Joan T Merrill; Paul R Fortin; Ian N Bruce; David Isenberg; Daniel J Wallace; Ola Nived; Gunnar Sturfelt; Rosalind Ramsey-Goldman; Sang-Cheol Bae; John G Hanly; Jorge Sánchez-Guerrero; Ann Clarke; Cynthia Aranow; Susan Manzi; Murray Urowitz; Dafna Gladman; Kenneth Kalunian; Melissa Costner; Victoria P Werth; Asad Zoma; Sasha Bernatsky; Guillermo Ruiz-Irastorza; Munther A Khamashta; Soren Jacobsen; Jill P Buyon; Peter Maddison; Mary Anne Dooley; Ronald F van Vollenhoven; Ellen Ginzler; Thomas Stoll; Christine Peschken; Joseph L Jorizzo; Jeffrey P Callen; S Sam Lim; Barri J Fessler; Murat Inanc; Diane L Kamen; Anisur Rahman; Kristjan Steinsson; Andrew G Franks; Lisa Sigler; Suhail Hameed; Hong Fang; Ngoc Pham; Robin Brey; Michael H Weisman; Gerald McGwin; Laurence S Magder
Journal:  Arthritis Rheum       Date:  2012-08

4.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

5.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity.

Authors:  Silvia Ferrari; Friedrich Scheiflinger; Manfred Rieger; Geert Mudde; Martine Wolf; Paul Coppo; Jean-Pierre Girma; Elie Azoulay; Christian Brun-Buisson; Fadi Fakhouri; Jean-Paul Mira; Eric Oksenhendler; Pascale Poullin; Eric Rondeau; Nicolas Schleinitz; Benoit Schlemmer; Jean-Louis Teboul; Philippe Vanhille; Jean-Paul Vernant; Dominique Meyer; Agnès Veyradier
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

Review 6.  Review of thrombotic thrombocytopenic purpura in the setting of systemic lupus erythematosus.

Authors:  F Musio; E M Bohen; C M Yuan; P G Welch
Journal:  Semin Arthritis Rheum       Date:  1998-08       Impact factor: 5.532

7.  ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.

Authors:  Sara K Vesely; James N George; Bernhard Lämmle; Jan-Dirk Studt; Lorenzo Alberio; Mayez A El-Harake; Gary E Raskob
Journal:  Blood       Date:  2003-03-13       Impact factor: 22.113

Review 8.  Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: Case series and review of literature.

Authors:  Nina Kello; Lara El Khoury; Galina Marder; Richard Furie; Ekaterini Zapantis; Diane Lewis Horowitz
Journal:  Semin Arthritis Rheum       Date:  2018-12-04       Impact factor: 5.532

9.  Clinical features and prognosis of patients with thrombotic thrombocytopenic purpura associated with systemic lupus erythematosus: a review of 25 cases.

Authors:  Ji Li; Jing-Jing Jiang; Chang-Yan Wang; Shan Jian; Yu Zhou; Ming-Sheng Ma; Xiao-Yan Tang; Lin Wang; Mei-Ying Quan; Yu Zhang; Juan Xiao; Yan-Yan He; Hong-Mei Song
Journal:  Ital J Pediatr       Date:  2019-04-29       Impact factor: 2.638

10.  Complement Inhibition in the Treatment of SLE-Associated Thrombotic Thrombocytopenic Purpura.

Authors:  Alexis Boneparth; L Nandini Moorthy; Lynne Weiss; Hariprem Rajasekhar; Susan Murphy; Richard A Drachtman
Journal:  Glob Pediatr Health       Date:  2015-01-30
View more
  1 in total

Review 1.  Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.

Authors:  John Paul Westwood; Marie Scully
Journal:  Ther Adv Hematol       Date:  2022-07-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.